Nanodrugs in Medicine and Healthcare: Pulmonary, Nasal and Ophthalmic Routes, and Vaccination

Müller‐Goymann, Christel C.; Paranjpe, Mukta

doi:10.1002/9783527800681.ch26

Cited by 3 publications

(2 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If the force of inhalation is insufficient, the dry powder will be deposited in the upper airways due to the mass of the particles [ 42 ]. In the MDI, high particle sizes also tend to lead to the deposition of the particles in the upper respiratory tract region despite the high speed of the generated aerosol [ 42 , 43 ].…”

Section: Nanoparticles For Inhaled Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Polymeric Nanoparticles for Inhaled Vaccines

et al. 2022

View full text Add to dashboard Cite

Many recent studies focus on the pulmonary delivery of vaccines as it is needle-free, safe, and effective. Inhaled vaccines enhance systemic and mucosal immunization but still faces many limitations that can be resolved using polymeric nanoparticles (PNPs). This review focuses on the use of properties of PNPs, specifically chitosan and PLGA to be used in the delivery of vaccines by inhalation. It also aims to highlight that PNPs have adjuvant properties by themselves that induce cellular and humeral immunogenicity. Further, different factors influence the behavior of PNP in vivo such as size, morphology, and charge are discussed. Finally, some of the primary challenges facing PNPs are reviewed including formulation instability, reproducibility, device-related factors, patient-related factors, and industrial-level scale-up. Herein, the most important variables of PNPs that shall be defined in any PNPs to be used for pulmonary delivery are defined. Further, this study focuses on the most popular polymers used for this purpose.

show abstract

Section: Nanoparticles For Inhaled Vaccinesmentioning

confidence: 99%

“…Moreover, depending on the location of deposition which is mainly affected by the particle size [ 43 ], the nanoparticles can interact with different cell types within the respiratory tract, such as epithelial cells and antigen-presenting cells.…”

Section: Nanoparticles For Inhaled Vaccinesmentioning

confidence: 99%

Polymeric Nanoparticles for Inhaled Vaccines

et al. 2022

View full text Add to dashboard Cite

show abstract

Nanotherapeutics in the treatment of acute respiratory distress syndrome

et al. 2021

View full text Add to dashboard Cite

Acute respiratory distress syndrome (ARDS) is a form of oxygenation failure primarily characterized by rapid inflammation resulting from a direct pulmonary or indirect systemic insult. ARDS has been a major cause of death in the recent COVID-19 outbreak wherein asymptomatic respiratory tract infection progresses to ARDS from pneumonia have emphasized the need for a reliable therapy for the disease. The disease has a high mortality rate of approximately 30–50%. Despite the high mortality rate, a dearth of effective pharmacotherapy exists that demands extensive research in this area. The complex ARDS pathophysiology which remains to be understood completely and the multifactorial etiology of the disease has led to the poor diagnosis, impeded drug-delivery to the deeper pulmonary tissues, and delayed treatment of the ARDS patients. Besides, critically ill patients are unable to tolerate the off-target side effects. The vast domain of nanobiotechnology presents several drug delivery systems offering numerous benefits such as targeted delivery, prolonged drug release, and uniform drug-distribution. The present review presents a brief insight into the ARDS pathophysiology and summarizes conventional pharmacotherapies available to date. Furthermore, the review provides an updated report of major developments in the nanomedicinal approaches for the treatment of ARDS. We also discuss different nano-formulations studied extensively in the ARDS preclinical models along with underlining the advantages as well as challenges that need to be addressed in the future.

show abstract

The nanotechnological approach for nasal delivery of peptide drugs: a comprehensive review

Zuglianello¹,

Lemos‐Senna²

2022

Journal of Microencapsulation

View full text Add to dashboard Cite

Nanodrugs in Medicine and Healthcare: Pulmonary, Nasal and Ophthalmic Routes, and Vaccination

Cited by 3 publications

References 95 publications

Polymeric Nanoparticles for Inhaled Vaccines

Polymeric Nanoparticles for Inhaled Vaccines

Nanotherapeutics in the treatment of acute respiratory distress syndrome

The nanotechnological approach for nasal delivery of peptide drugs: a comprehensive review

Contact Info

Product

Resources

About